Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou, China.
J Exp Clin Cancer Res. 2018 Aug 15;37(1):193. doi: 10.1186/s13046-018-0866-4.
Holliday junction recognition protein (HJURP) has been implicated in many cancers including hepatocellular carcinoma (HCC). However, the underlying mechanism by which HJURP promotes HCC cell proliferation remains unclear.
RT-qPCR and immunohistochemistry were used to detect HJURP expression in HCC and adjacent tumor tissues and HCC cell lines. The localization of p21 were determined by immunofluorescence and western blot. Co-immunoprecipitation and western blot were used to validate the p21 stability and signaling pathways affected by HJURP. The effects of HJURP on HCC cell proliferation were assessed both in vivo and in vitro. The ERK1/2 pathway inhibitor U0126 and AKT pathway agonist SC-79 were used to treat HCC cell lines for further mechanistic investigations.
HJURP expression was higher in HCC tissues than in para-tumor tissues. Moreover, ectopic HJURP expression facilitated the proliferation of HCC cells, whereas the depletion of HJURP resulted in decreased cell growth in vitro and in vivo. Furthermore, the effects of HJURP silencing were reversed by p21 knockdown. Likewise, p21 overexpression inhibited cell growth ability mediated by HJURP elevation. Mechanistically, HJURP destabilized p21 via the MAPK/ERK1/2 and AKT/GSK3β pathways, which regulated the nucleus-cytoplasm translocation and ubiquitin-mediated degradation of p21. Clinically, high HJURP expression was correlated with unfavorable prognoses in HCC individuals.
Our data revealed that HJURP is an oncogene that drives cell cycle progression upstream of p21 in HCC. These findings may provide a potential therapeutic and prognostic target for HCC.
Holliday 连接点识别蛋白(HJURP)已被发现与多种癌症有关,包括肝细胞癌(HCC)。然而,HJURP 促进 HCC 细胞增殖的潜在机制尚不清楚。
使用 RT-qPCR 和免疫组织化学检测 HCC 及相邻肿瘤组织和 HCC 细胞系中 HJURP 的表达。通过免疫荧光和 Western blot 确定 p21 的定位。通过共免疫沉淀和 Western blot 验证 HJURP 对 p21 稳定性和信号通路的影响。通过体内和体外实验评估 HJURP 对 HCC 细胞增殖的影响。使用 ERK1/2 通路抑制剂 U0126 和 AKT 通路激动剂 SC-79 处理 HCC 细胞系,进一步进行机制研究。
与癌旁组织相比,HJURP 在 HCC 组织中的表达水平更高。此外,异位表达 HJURP 促进了 HCC 细胞的增殖,而 HJURP 的耗竭导致体外和体内细胞生长减少。此外,p21 敲低可逆转 HJURP 沉默的作用。同样,p21 的过表达抑制了 HJURP 上调介导的细胞生长能力。机制上,HJURP 通过 MAPK/ERK1/2 和 AKT/GSK3β 通路使 p21 不稳定,从而调节 p21 的核质转位和泛素介导的降解。临床上,高 HJURP 表达与 HCC 患者的不良预后相关。
我们的数据表明,HJURP 是一种癌基因,它在 HCC 中 p21 的上游驱动细胞周期进程。这些发现可能为 HCC 提供一个潜在的治疗和预后靶点。